ArticleThe Laryngoscope2026
Modified Sleep Apnea Severity Index and Cardiovascular Risk in CPAP-Intolerant OSA Patients.
Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modified Sleep Apnea Severity Index and Cardiovascular Risk in CPAP-Intolerant OSA Patients.The Laryngoscope · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe modified sleep apnea severity index (mSASI) combines patient anatomy, weight, sleep study metrics, and symptoms into a composite OSA index ranging from 1 (least severe) to 3 (most severe). Our study aims to assess the association between the mSASI and cardiovascular (CV) risk factors in patients undergoing sleep surgery. STUDY
designRetrospective cohort review.
settingSingle-institution tertiary care center.
methodsCPAP-intolerant OSA patients who underwent hypoglossal nerve stimulation, maxillomandibular advancement, or expansion sphincter pharyngoplasty at our institution from 2014 to 2021 were included. Cardiovascular comorbidities and 5-year Framingham Risk Score (FRS) were assessed at the preoperative visit. Chi-squared and Wilcoxon rank sum test analyses were performed using R Studio.
resultsOf the 209 patients included, 118 had an mSASI = 1, 71 had an mSASI = 2, and 20 had an mSASI = 3. Patients with an mSASI of 2 or 3 were more likely to have HTN (33% vs 51%, p = 0.011). Baseline mSASI (β = 4.4, 95% CI 0.04-8.7) and age (β = 1.3, 95% CI 1.0-1.6) were independently associated with increased FRS on multivariable linear regression (p < 0.05). However, this association did not persist in secondary models excluding constituent components of mSASI and FRS.
conclusionsThe mSASI may offer additional benefits in assessing OSA risk severity based on CV risk factors compared to the AHI alone. However, given that this association was not replicated in the secondary analysis, further research is needed to evaluate the utility beyond its individual factors and traditional metrics alone. LEVEL OF EVIDENCE: 4:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.